The fight over 340B contract pharmacy loomed large in stakeholders’ comments last week on a proposed federal regulation to revamp the 340B program’s administrative dispute resolution system.
Health care provider groups, citing manufacturers’ contract pharmacy policies, said they want the U.S. Health Resources and Services Administration’s ADR final rule to make it clear that 340B covered entities may file petitions against manufacturers that will not ship 340B-purchased drugs to more than one contract pharmacy per entity. Manufacturer groups meanwhile criticized HRSA for failing to address 340B drug diversion and duplicate discounts. Practically all companies that impose conditions on 340B contract pharmacy cite diversion and duplicate discounts as their main motivations.
The fight over 340B contract pharmacy loomed large in stakeholders’ comments last week on a proposed federal regulation to revamp the 340B program’s administrative dispute resolution system.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
